Our Business
With the rapidly growing global metabolic disease epidemic, which includes diabetes and obesity, there is a significant need to bring safer, more effective medications to physicians and patients world-wide. InteKrin’s business strategy, under the guidance of InteKrin’s experienced Management Team and world-class Scientific Advisory Board and Board of Directors , is to build a robust portfolio of high-potential products through in-licensing clinical-stage therapeutic candidates to meet the growing patient needs. The InteKrin team uses its capabilities to rapidly and effectively shepherd these therapeutic candidates through critical development stages to de-risk them and maximize their commercial potential.
Read More
Recent News
June 10, 2009
InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides anti-diabetic efficacy consistent with maximal dose thiazolidinedione (TZD) therapy but with less hematocrit reduction and weight gain.
Read More March 11, 2009
InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study of INT131
Read More